Atri A, Shaughnessy LW et al. Long-term course and effectiveness of combination therapy in Alzheimer disease. Alzheimer Dis Assoc Disord 2008;22: 209-21.
Ballard CG, Waite J et al. Atypical antipsychotics for aggression and psychosis in Alzheimer´s disease. Cochrane Database Syst Rev 2006, Issue 1. Art. No: CD003476. DOI: 10.1002/14651858.CD003476.pub2.
Health Quality Ontario 2013. Vitamin B and cognitive function: an evidence-based analysis. Ont Health Technol Assess Ser. 2013 Nov 1;13(23):1- 45.
Howard R, McShane R et al. Donepezil and memantine for moderate-to-servere Alzheimer´s Disease, NEJM, 2012; 366: 893-903. DOI: 10.1056/ NEJMoa1106668
Lopez OL, Becker JT et al. Long-term effects of the concomitant use of memantine with cholinesterase inhibition in Alzheimer disease. J Neurol Neurosurg Psychiatry 2009; 80: 600-7.
McShane R1, Westby MJ, Roberts E, Minakaran N, Schneider L, Farrimond LE, Maayan N, Ware J, Debarros J. Memantine for dementia. Cochrane Database Syst Rev. 2019 Mar 20;3:CD003154. doi: 10.1002/14651858.CD003154.pub6.
NICE 2011. Donepezil, galantamine, rivastagmine and memantine for the treatment of Alzheimer´s disease. NICE technology appraisal guidance 217.
SBU Statens beredning för medicinsk utvärdering. 2006. Demenssjukdomar. Rapportnummer 172.
Smith AD; Refsum H, Bottiglieri T, Fenech M, Hooshmand B, McCaddon A, Miller JW, Rosenberg IH, Obeid R. “Homocysteine and Dementia: An International Consensus Staement”, J Alheimers Dis, 2018; 62(2):561-570.
Vägverkets författningssamling, VVFS 2008:166. Vägverkets föreskrifter om ändring i föreskrifterna (VVFS 2008:158) om medicinska krav för innehav av körkort mm, 10:e kapitlet demens och andra kognitiva störningar
